Boardroom Radio Interview with Mesoblast Chief Executive NEW YORK, Feb. 2, 2014 (GLOBE NEWSWIRE) -- Audio link - http://www.brrmedia.com/event/120127BRR    Today at Boardroom Radio (BRR) we're once again joined by Mr Silviu Itescu, who is...

New Japanese Regenerative Medicine Legislation and Commercial Opportunities for Stem Cell Products NEW YORK and MELBOURNE, Australia, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today gave an update on new legislation which provides a...

MESOBLAST REPORTS POSITIVE INTERIM RESULTS IN PHASE 2 TRIAL OF PROPRIETARY ADULT STEM CELLS FOR INTERVERTEBRAL DISC REPAIR Mesoblast's Phase 2 trial of allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) injected into damaged intervertebral discs has now completed six-month follow-up for all 100...

Mesoblast Receives FDA Clearance for Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Patients With Active Rheumatoid Arthritis Key Points: Mesoblast receives clearance from United States Food and Drug Administration (FDA) to begin Phase 2 trial of proprietary allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells...